|
Sep 30
|
Top Research Reports for Apple, Tesla & T-Mobile US
|
|
Sep 30
|
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
|
|
Sep 27
|
Volkswagen, Novartis could surprise in Q3 earnings season, UBS analysts warn
|
|
Sep 25
|
Generate:Biomedicines and Novartis link on protein therapeutics development
|
|
Sep 24
|
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
|
|
Sep 6
|
After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN
|
|
Sep 6
|
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
|
|
Sep 6
|
Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise
|
|
Sep 5
|
Jim Cramer Says It Will Take Time For Novartis AG (NVS) To ‘Get The Attention Of Investors’
|
|
Sep 5
|
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
|
|
Sep 4
|
Novartis builds out radiopharma production with expansion, new factory
|
|
Sep 4
|
Is Novartis AG (NVS) the Best Cancer Stock to Buy Now?
|
|
Sep 3
|
Novartis (NVS) Upgraded to Buy: Here's What You Should Know
|
|
Aug 31
|
ESC 2024: Study highlights potential for Novartis to differentiate in HF space
|
|
Aug 29
|
Novartis teams up with Lindy Biosciences to improve biologic delivery
|
|
Aug 29
|
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
|
|
Aug 29
|
Novartis’ Phase III trial of Leqvio in ASCVD patients meets primary endpoints
|
|
Aug 28
|
Novartis AG (NVS): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
|
Aug 28
|
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
|
|
Aug 28
|
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
|